Skip to main content

Table 2 High-dose chemotherapy/ASCT

From: Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution

ParameterOverall cohortGroup 1 (3–4 × 106 CD34+ cells /kg bw)Group 2 (2–2.5 × 106 CD34+ cells /kg bw)P value Group 1 vs. 2Group 3 (< 2 × 106 CD34+ cells /kg bw)
ASCTs analyzed, n1488653/9
Sequential ABSCTs, n (%)   / 
 First142 (96)86 (100)53 (100)3 (33)
 Second5 (3)0 (0)0 (0)5 (56)
 Third1 (1)0 (0)0 (0)1 (11)
Remission pre ABSCT, n (%)   0.168a 
 CR2 (1)2 (2)0 (0)0 (0)
 nCR38 (26)28 (33)9 (17)1 (11)
 VGPR48 (32)26 (30)21 (40)1 (11)
 PR45 (30)21 (24)18 (34)6 (67)
 MR4 (3)3 (3)1 (2)0 (0)
 SD1 (1)0 (0)1 (2)0 (0)
 PD6 (4)2 (2)3 (6)1 (11)
 NA4 (3)4 (5)0 (0)0 (0)
Median age at ASCT, years (range)61 (41–75)61 (44–73)62 (41–72)0.88660 (50–75)
Transplanted PBSCs
 Median transplanted CD34+ cells ×106/kg (range)3.2 (1.7–4.0)3.6 (3.0–4.0)2.3 (2.0–2.5)< 0.0011.9 (1.7–1.99)
 Median vitality, % (range)79 (53–93)76 (53–93)81 (58–93)0.01280 (66–93)
HD chemotherapy, n (%)   / 
 Melphalan 2 × 100 mg/m2146 (99)85 (99)53 (100)8 (89)
 Dose reduction2 (1)1 (1)0 (0)1 (11)
Remission post ASCT, n (%)   0.316b 
 CR15 (10)11 (13)4 (8)0 (0)
 nCR42 (28)30 (35)11 (21)1 (11)
 VGPR54 (36)27 (31)22 (42)5 (56)
 PR25 (17)11 (13)12 (23)2 (22)
 MR5 (3)3 (3)2 (4)0 (0)
 SD1 (1)1 (1)0 (0)0 (0)
 PD2 (1)2 (2)0 (0)0 (0)
 NA4 (3)1 (1)2 (4)1 (11)
  1. a/bCR/nCR/VGPR versus PR/MR/SD/PD.
  2. ASCT autologous blood stem cell transplantation; CR complete remission; HD high-dose; MR minimal response; NA not available; nCR near complete remission; PD progressive disease; PR partial remission; SD stable disease; VGPR very good partial remission; vs., versus